A Bioinformatics Approach for the Phenotype Prediction of Nonsynonymous Single Nucleotide Polymorphisms in Human Cytochromes P450

Nonsynonymous single nucleotide polymorphisms (nsSNPs) in coding regions that can lead to amino acid changes may cause alteration of protein function and account for susceptivity to disease and altered drug response. Identification of deleterious nsSNPs from tolerant nsSNPs is important for characterizing the genetic basis of human disease, assessing individual susceptibility to disease, understanding the pathogenesis of disease, identifying molecular targets for drug treatment, and conducting individualized pharmacotherapy. Numerous nsSNPs have been found in genes coding for human cytochromes P450 (P450s), but there is poor knowledge on the relationship between the genotype and phenotype of nsSNPs in P450s. We have identified 791 validated nsSNPs in 57 validated human CYP genes from the National Center for Biotechnology Information Database of Single Nucleotide Polymorphism and Swiss-Prot database. Using the polymorphism phenotyping (PolyPhen; http://genetics.bwh.harvard.edu/pph) and sorting intolerant from tolerant (SIFT; http://blocks.fhcrc.org/sift/SIFT.html) algorithms, 39 to 43% of nsSNPs in CYP genes were predicted to have functional impacts on protein function. There was a significant concordance between the predicted results using the SIFT and PolyPhen algorithms. A prediction accuracy analysis found that approximately 70% of nsSNPs were predicted correctly as damaging. Of nsSNPs predicted as deleterious, the prediction scores by the SIFT and PolyPhen algorithms were significantly associated with the numbers of nsSNPs with known phenotype confirmed by benchmarking studies, including site-directed mutagenesis analysis and clinical association studies. These amino acid substitutions are supposed to be the pathogenetic basis for the alteration of P450 enzyme activity and the association with disease susceptivity. This prediction analysis of nsSNPs in human CYP genes would be useful for further genotype-phenotype studies on individual differences in drug clearance and clinical response.

[1]  J Deisenhofer,et al.  Crystal structure of hemoprotein domain of P450BM-3, a prototype for microsomal P450's. , 1993, Science.

[2]  F. Kamali,et al.  Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. , 2004, Pharmacogenetics.

[3]  M. Tusié-Luna,et al.  R339H and P453S: CYP21 mutations associated with nonclassic steroid 21-hydroxylase deficiency that are not apparent gene conversions. , 1992, Molecular endocrinology.

[4]  T. Massey,et al.  Analysis of CYP2A Contributions to Metabolism of 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone in Human Peripheral Lung Microsomes , 2007, Drug Metabolism and Disposition.

[5]  Shufeng Zhou,et al.  Identification of the human liver cytochrome P450 isoenzyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[6]  D. Flockhart,et al.  Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism , 2002, Clinical pharmacokinetics.

[7]  D. Chasman,et al.  Predicting the functional consequences of non-synonymous single nucleotide polymorphisms: structure-based assessment of amino acid variation. , 2001, Journal of molecular biology.

[8]  H. Mohrenweiser,et al.  Cloning of CYP2J2 gene and identification of functional polymorphisms. , 2002, Molecular pharmacology.

[9]  J. Halpert,et al.  Analysis of mammalian cytochrome P450 structure and function by site-directed mutagenesis. , 2001, Current drug metabolism.

[10]  H. Refsum,et al.  Impact of the Ultrarapid CYP2C19*17 Allele on Serum Concentration of Escitalopram in Psychiatric Patients , 2008, Clinical pharmacology and therapeutics.

[11]  I. M. Jones,et al.  Many amino acid substitution variants identified in DNA repair genes during human population screenings are predicted to impact protein function. , 2004, Genomics.

[12]  M. Orozco,et al.  Characterization of disease-associated single amino acid polymorphisms in terms of sequence and structure properties. , 2002, Journal of molecular biology.

[13]  Warren C. Lathe,et al.  Prediction of deleterious human alleles. , 2001, Human molecular genetics.

[14]  Steven Henikoff,et al.  SIFT: predicting amino acid changes that affect protein function , 2003, Nucleic Acids Res..

[15]  J Kirchheiner,et al.  The clinical role of genetic polymorphisms in drug-metabolizing enzymes , 2008, The Pharmacogenomics Journal.

[16]  D. Cooper,et al.  Assessing the relative importance of the biophysical properties of amino acid substitutions associated with human genetic disease , 2002, Human mutation.

[17]  A. Zhernakova,et al.  Detecting shared pathogenesis from the shared genetics of immune-related diseases , 2009, Nature Reviews Genetics.

[18]  S. Murphy,et al.  Functional characterization of CYP2A13 polymorphisms. , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[19]  Joseph H. Nadeau,et al.  Single nucleotide polymorphisms: Tackling complexity , 2002, Nature.

[20]  P. Dayer,et al.  Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. , 1998, The Journal of pharmacology and experimental therapeutics.

[21]  P. Bork,et al.  Human non-synonymous SNPs: server and survey. , 2002, Nucleic acids research.

[22]  Magnus Ingelman-Sundberg,et al.  Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. , 2007, Pharmacology & therapeutics.

[23]  P. Dayer,et al.  A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. , 1999, The Journal of pharmacology and experimental therapeutics.

[24]  D. Russell,et al.  Clinical importance of the cytochromes P450 , 2002, The Lancet.

[25]  B. Monsarrat,et al.  Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[26]  O Pelkonen,et al.  Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism , 1999, FEBS letters.

[27]  Wei Duan,et al.  Clinical pharmacogenetics and potential application in personalized medicine. , 2008, Current drug metabolism.

[28]  H. Blanché,et al.  Novel mutations in CYP21 detected in individuals with hyperandrogenism. , 2002, The Journal of clinical endocrinology and metabolism.

[29]  Jose Cosme,et al.  Crystal structure of human cytochrome P450 2C9 with bound warfarin , 2003, Nature.

[30]  D. Lewis,et al.  Identification of key residues in rabbit liver microsomal cytochrome P450 2B4: importance in interactions with NADPH-cytochrome P450 reductase. , 2000, Journal of biochemistry.

[31]  J. Goldstein,et al.  Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. , 2001, Pharmacogenetics.

[32]  M. Forest,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society 17�-Hydroxylase/17,20-Lyase Deficiency as a Model to Study Enzymatic Activity Regulation: Role of Phosphorylation* , 2022 .

[33]  S. Kasif,et al.  Structural location of disease-associated single-nucleotide polymorphisms. , 2003, Journal of molecular biology.

[34]  M. Caggana,et al.  Genetic polymorphisms of the human CYP2A13 gene: identification of single-nucleotide polymorphisms and functional characterization of an Arg257Cys variant. , 2002, The Journal of pharmacology and experimental therapeutics.

[35]  R. Harris,et al.  Altered gene expression profiles in the frontal cortex of cirrhotic alcoholics. , 2007, Alcoholism, clinical and experimental research.

[36]  H. Klenk,et al.  Identification and functional characterization of eight CYP3A4 protein variants. , 2001, Pharmacogenetics.

[37]  M. Kitagawa,et al.  CYP2A6*6, a Novel Polymorphism in Cytochrome P450 2A6, Has a Single Amino Acid Substitution (R128Q) That Inactivates Enzymatic Activity* , 2001, The Journal of Biological Chemistry.

[38]  Shufeng Zhou.  Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. , 2008, Current drug metabolism.

[39]  Hiroshi Yamazaki,et al.  A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur. , 2002, Pharmacogenetics.

[40]  Jose Cosme,et al.  Crystal Structures of Human Cytochrome P450 3A4 Bound to Metyrapone and Progesterone , 2004, Science.

[41]  P. Stenson,et al.  Human Gene Mutation Database: towards a comprehensive central mutation database , 2007, Journal of Medical Genetics.

[42]  Alan F. Scott,et al.  Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders , 2002, Nucleic Acids Res..

[43]  J. Miners,et al.  Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. , 1998, British journal of clinical pharmacology.

[44]  Dmitri V. Zaykin,et al.  Effectiveness of computational methods in haplotype prediction , 2002, Human Genetics.

[45]  Wei Duan,et al.  Insights into the structure, function, and regulation of human cytochrome P450 1A2. , 2009, Current drug metabolism.

[46]  S. Henikoff,et al.  Accounting for human polymorphisms predicted to affect protein function. , 2002, Genome research.

[47]  Geoffrey B. Nilsen,et al.  Whole-Genome Patterns of Common DNA Variation in Three Human Populations , 2005, Science.

[48]  N. Kamatani,et al.  Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese , 2006, Pharmacogenetics and genomics.

[49]  J. Lafitte,et al.  Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. , 1997, Pharmacogenetics.

[50]  Y. Fujii‐Kuriyama,et al.  Molecular analysis of patient and carrier genes with congenital steroid 21-hydroxylase deficiency by using polymerase chain reaction and single strand conformation polymorphism. , 1993, The Journal of clinical investigation.

[51]  J. Moult,et al.  SNPs, protein structure, and disease , 2001, Human mutation.

[52]  R. Kofler,et al.  CYP11B1 mutations causing non-classic adrenal hyperplasia due to 11 beta-hydroxylase deficiency. , 1997, Human molecular genetics.

[53]  P. Dayer,et al.  An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. , 1998, Pharmacogenetics.

[54]  M. Cargill.  Characterization of single-nucleotide polymorphisms in coding regions of human genes , 1999, Nature Genetics.

[55]  Eric F. Johnson,et al.  The Structure of Human Microsomal Cytochrome P450 3A4 Determined by X-ray Crystallography to 2.05-Å Resolution* , 2004, Journal of Biological Chemistry.

[56]  Eric D Wieben,et al.  Human aromatase: gene resequencing and functional genomics. , 2005, Cancer research.

[57]  R. Auchus,et al.  Pitfalls in characterizing P450c17 mutations associated with isolated 17,20-lyase deficiency. , 2001, The Journal of clinical endocrinology and metabolism.

[58]  S. Henikoff,et al.  Amino acid substitution matrices from protein blocks. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[59]  D E McRee,et al.  Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. , 2000, Molecular cell.

[60]  T. Date,et al.  Mutation of histidine 373 to leucine in cytochrome P450c17 causes 17 alpha-hydroxylase deficiency. , 1993, The Journal of biological chemistry.

[61]  G R Wilkinson,et al.  A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. , 1998, The Journal of pharmacology and experimental therapeutics.

[62]  Qing-Yu Zhang,et al.  Characterization of CYP2A13*2, a Variant Cytochrome P450 Allele Previously Found to Be Associated with Decreased Incidences of Lung Adenocarcinoma in Smokers , 2008, Drug Metabolism and Disposition.

[63]  S. Henikoff,et al.  Predicting the effects of amino acid substitutions on protein function. , 2006, Annual review of genomics and human genetics.